Comparison of Combined Nebulization of Salbutamol-Ipratropium Bromide with Salbutamol Alone in Children with Mild and Moderate Acute Asthma by Raja, Naima Fazil et al.
208                                                                             Journal of Rawalpindi Medical College (JRMC); 2020; 24(3): 208-213 
Original Article 
 
Comparison of Combined Nebulization of Salbutamol-
Ipratropium Bromide with Salbutamol Alone in Children 
with Mild and Moderate Acute Asthma  
Naima Fazil Raja1, Asmat Perveen2, Imran Mahmood Khan3 Maqbool Hussain4, Jai Krishin5,  
Sajid Hussain Sherazi6 
               1 Consultant Paediatrician, Department of Paediatrics,  
          THQ Hospital, Taxila.  
                2 Senior Registrar, Department of Paediatrics,  
          Benazir Bhutto Hospital, Rawalpindi.  
               3 Associate Professor, Department of Paediatrics,           
          Islamabad Medical & Dental College, Islamabad.  
4,5 Professor, Department of Paediatrics,  
Children Hospital, PIMS, Islamabad.  
6 Assistant Professor, Department of Paediatrics,  
Niazi Medical & Dental College, Sargodha.
Author’s Contribution 
1,2,3.4,5 Conception of study  
1,2,3 Experimentation/Study conduction  
1,2,3 Analysis/Interpretation/Discussion  
1,2,3,6 Manuscript Writing 
4,5,6 Critical Review 
 
Corresponding Author 
Dr. Imran Mahmood Khan, 
Associate Professor, 
Department of Paediatrics,  




Received:  07/03/2020 
Accepted:  10/07/2020 
 
Cite this Article: Raja, N.F., Perveen, A., Khan, I.M., 
Hussain, M., Krishin, J., Sherazi, S.H. Comparison of 
Combined Nebulization of Salbutamol-Ipratropium 
Bromide with Salbutamol Alone in Children with Mild 
and Moderate Acute Asthma. Journal of Rawalpindi 
Medical College. 30 Sep. 2020; 24(3): 208-213. 
DOI:  https://doi.org/10.37939/jrmc.v24i3.1213 
    Conflict of Interest: Nil 
    Funding Source: All 
investigations and treatment of 






Introduction: The β2 agonists are potent bronchodilators but their repeated and high doses are related to 
adrenergic side effects. While ipratropium bromide, an anticholinergic bronchodilator has less adverse effects. 
Objective: To compare the efficacy of combined nebulization of salbutamol-ipratropium bromide with 
salbutamol alone in children with mild and moderate acute asthma. 
Materials and Methods: This randomised control trial was done on 80 children aged 5 to 12 years who presented 
with mild to moderate acute asthma in the emergency department of Children Hospital of Pakistan Institute of 
Medical Sciences (PIMS) from July 2014 to June 2016 and randomized into 2 groups. In the experimental group 
each child received 2 nebulizations of combined salbutamol (5mg) and ipratropium Bromide (0.25mg) at 
presentation and 20 minutes later. Similarly, each child of the control group received 2 nebulizations of 5mg 
Salbutamol and 2 ml of Normal saline. Asthma clinical score (ACS) was assessed at baseline and then after every 
20 minutes up to one hour after the presentation. 
Results: In the experimental group, the mean + SD ACS at presentation and 60 minutes were 3.50±1.8 and 
3.45±1.7 respectively with mean + SD change in ACS of 0.05 ± 0.1. In the control group, the mean + SD ACS at 
presentation and 60 minutes were 3.70 ± 1.2 and 3.60 ± 1.9, respectively with mean + SD change in ACS of 0.1 ± 
0.7. This difference in mean + SD change in ACS between 2 groups was not statistically significant (P=0.6560). 
Conclusion: There is no statistically significant benefit of adding ipratropium bromide with salbutamol 
nebulization as compared to salbutamol alone for the management of children with mild to moderate asthma 
attacks.  
Keywords: Asthma, ipratropium bromide, salbutamol, acute asthma, asthma clinical score. 
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Introduction 
 
Asthma is defined as “chronic inflammatory condition 
of the lung airways resulting in episodic airflow 
obstruction”.1 Symptoms of asthma include wheeze, 
shortness of breath, chest tightness, and disturbed 
night sleep resulting in frequent absences from 
schools.2,3 Bronchial asthma is precipitated by common 
environmental triggers including dust and cold air 
etc.4  Fever,  antibiotics, hay fever,  raised IgE levels, 
exposure to passive smoking, living in urban areas and 
family history of asthma are significant risk factors for 
the development of asthma in children.5,6 
In Pakistan mean prevalence of asthma in children is 
10.2%.7  Exact numbers of annual admissions due to 
childhood asthma are not known in many low and 
middle-income countries including Pakistan due to 
lack of statistics.8  
Symptoms of acute exacerbation of asthma range from 
mild to life-threatening. Acute asthma is defined as 
“an acute or sub-acute deterioration in symptoms that 
cause distress to the extent that visit to the health care 
provider or treatment with systemic corticosteroids 
become necessary”.9 Acute exacerbations of asthma 
are associated with increased risk of hospital 
admissions and deaths and exacerbations also increase 
disease progression.10 
β2 agonists are potent bronchodilators but their 
repeated and high doses are related to adrenergic side 
effects. Ipratropium bromide causes slow onset but the 
long duration of anticholinergic bronchodilatation 
with less adverse effects than those of β2 agonists.1,11  
Previous studies have already established the 
beneficial effects of salbutamol-ipratropium bromide 
combinations in acute severe asthma in form of 
reducing hospitalization rate as well as the duration of 
hospitalization. So now its standard treatment in acute 
severe asthma.12,13,14,15 But its role in mild and 
moderate asthma is controversial as some studies 
found it beneficial16 while others do not.17 
In Pakistan, there has been some work done on the 
effect of a combination of salbutamol with ipratropium 
bromide in children with moderate and severe 
exacerbation of acute asthma18,19 but no work is done 
in mild and moderate exacerbation of asthma. 
Therefore this study is carried out to increase our 
horizon in the management of mild and moderate 




Materials and Methods 
 
After seeking permission from the institutional ethics 
review board, this randomized controlled trial was 
done at the emergency department of Children 
Hospital of Pakistan Institute of Medical Sciences 
(PIMS), Islamabad from July 2014 to June 2016. 
Children with mild to moderate acute asthma aged 5 
to 12 years were included in this study. Asthma 
Clinical Score, PRAM (Preschool Respiratory 
Assessment Measure) was used to assess the severity 
of acute asthma.20,21 Mild severity corresponds to 
asthma clinical score (ACS) of 0 to 4 and moderate 
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Table 1: Asthma Clinical Score (PRAM) 
Children with severe exacerbation of acute asthma, 
cystic fibrosis, known cardiac, renal, or 
immunodeficiency disease, and consolidation on chest 
x-ray were excluded from the study. A total of 80 
children (40 in each group) were taken as a sample 
size by using the WHO sample size calculator with the 
following values; Level of significance=5%, confidence 
interval=95%, population mean=3.71, anticipated 
population mean=4.86, Pooled SD=1.01.22 
80 children fulfilling the above-mentioned inclusion 
criteria were registered in the study by using 
systematic sampling.  A computer-generated table of 
random numbers was used to randomize the 
registered children into two study groups; 
Experimental and Control. Each child of the 
experimental group received 2 nebulizations of 
combined salbutamol (5mg) and ipratropium Bromide 
(0.25mg) at presentation and 20 minutes later. 
Similarly, each child of the control group received 2 
nebulizations of 5mg salbutamol and 2 ml of normal 
saline at presentation and 20 minutes later. ACS was 
assessed at presentation and then after every 20 
minutes up to one hour after the presentation. All 
inhaled therapies were delivered from standard 
oxygen is driven hospital nebulizer through a tight-
fitting face mask. 
At the time of registration patient’s demographic 
characteristics (age, sex) and details of illness were 
recorded on a specially designed proforma for this 
study. The data was entered and analysed using SPSS 
version 20.  For continuous variables such as age, ACS 
at presentation, and at 60 minutes, mean and standard 
deviation were calculated. Frequencies and 
percentages were calculated for categorical variables 
such as gender. For comparison of mean change in 
ACS between the two studies groups, an independent 





In this study, 80 children (40 in each group) with mild 
and moderate exacerbation of asthma were enrolled. 
Out of 80 children, 47 (59%) were males while 33 (41%) 
were females. The male to female ratio was 1.4:1.   
Mean + SD of age, duration of symptoms before 
presentation, and ACS are shown in Table 2.  
Frequency and percentages of age breakdown of 
children, duration, and symptoms of current illness 
and severity of exacerbation of acute asthma are 
shown in Table 2.  
 
Signs 0 1 2 3 
Suprasternal 
Indrawing 
Absent  Present  
Scalene retractions Absent  Present  





stethoscope/ silent chest with 
minimum air entry 






on room air 





   
Mild 0-4    
Moderate 5-8    
Severe 9-12    
Impending 
Respiratory Failure 
Regardless of score, 
presence of lethargy, 
cyanosis, decreasing 
respiratory effort, 
and/or rising pCO2 
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Table 2: Descriptive Statistics of Asthma Patients 
(n=80) 
Characteristics Mean+SD 
Age (years) 8.3 ± 4.6 
Duration of symptoms before the 
presentation (days) 
4.8 ± 2.9 
Asthma Clinical score  3.8 ± 1.9 
Variables n (%) 
Age  
   Less than 8 Years 
   From 8 to 10 Years 






Duration of current illness 
   Less than 3 days 
   From 3 to 5 days 





Upper respiratory tract infection 
   Present 




Exacerbation of acute asthma 
   Mild 





In the experimental group, the mean + SD ACS at 
presentation and 60 minutes were 3.50 ± 1.8 and 3.45 ± 
1.7 respectively with a mean + SD decrease in ACS of 
0.05 ± 0.1.  In the control group, the mean + SD ACS at 
presentation and 60 minutes were 3.70 ± 1.2 and 3.60 ± 
1.9, respectively with a mean + SD decrease in ACS of 
0.1 ± 0.7. This difference in mean change in clinical 
asthma score in groups was not statistically significant 
(P=0.6560) as shown in Table 3. 
 
Table 3: Comparison of Asthma Clinical Score at 
Presentation and 60 minutes in experimental and 






























Acute exacerbation of asthma is the most common 
pediatric emergency and results in nearly 500,000 
annual admissions in Pediatric intensive care units in 
the USA.23 A study done in Manchester showed that 
10% of pediatric asthma patients had unscheduled 
doctor visits and hospital admission due to acute 
exacerbations of asthma.24  
In our study, in the experimental group, the mean + 
SD decrease in ACS is 0.05 ± 0.1 while in the control 
group, it is 0.1 ± 0.7. This difference in a mean decrease 
in clinical asthma score in two groups was not 
statistically significant (p=0.6560). The findings of our 
study are comparable to those of the following studies.  
Wyatt and his colleagues in their study conducted on 
children with moderate acute asthma found that the 
addition of ipratropium bromide to salbutamol did not 
significantly reduce admission rates as compare to 
salbutamol alone when administered through a 
metered-dose inhaler.25 
Harumdini and colleagues from Indonesia conducted 
a study on 46 children of mild and moderate asthma 
attacks by comparing the efficacy of salbutamol-
ipratropium bromide nebulization to salbutamol 
alone. The mean decrease in ACS after 60 minutes was 
4.86 in the experimental group as compared to that of  
3.71 in the control group which was not statistically 
significant (p>0.05).22  
Similarly, Kumaratne and Gunawardane from 
California USA carried out a prospective, randomised, 
double-blind study in 53 children of mild to moderate 
asthma to determine any advantage of adding 
Ipratropium bromide nebulization to albuterol 
nebulization. Mean + SD ACS was 2.92 + 1.09 in the 
control group and 3.13 + 1.15 in the ipratropium 
bromide group which was not statistically significant 
(p=0.53).26 
Craven conducted a study that showed that even in 
the treatment of hospitalized patients, the addition of 
ipratropium bromide to salbutamol did not result in a 
statistically significant decrease in mean length of 
hospital stay.27  
Rayner and coworkers from Nottingham, United 
Kingdom carried out a randomized controlled study in 
admitted children of acute asthma of all severities to 
establish whether giving nebulized ipratropium after 
salbutamol conferred any therapeutic benefit over 
salbutamol alone. A total of 37 children, age 2 to 15 
years were enrolled in the study and were randomly 
received either salbutamol and placebo (normal saline) 
or salbutamol and ipratropium bromide. The 
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investigators found no significant difference in the 
mean clinical asthma score, peak expiratory flow rate, 
or mean length of stay in hospital between the two 
groups.17 
Cochrane review of 7 studies by Vezina also showed 
that in acute asthma with different severities, a 
combination of salbutamol with ipratropium bromide 
is not effective in improving ACS as compared to that 
of salbutamol alone.28 
While some other studies show contrary results to 
those of our study.  
Afzal khan and colleagues in their study done in 
Peshawar on children presenting with moderate to 
severe asthma found the beneficial effect of the 
addition of ipratropium bromide to salbutamol in 
terms of earlier discharge from hospital.19 
A similar study done by Donohue in adults shows that 
combined ipratropium bromide with salbutamol 
through metered-dose inhaler significantly improved 
bronchodilatation than that of salbutamol alone.29 
Chakraborti et al from India conducted a double-blind 
randomised controlled study on 60 children age 5 to 15 
years to evaluate the effect of the addition of 
ipratropium bromide to salbutamol for the treatment 
of mild to moderate exacerbation of asthma. The 
unique thing of this study is that they administer 
drugs through a metered-dose inhaler and spacer 
instead of a nebulizer. They found statistically 
significant improvement in percent predicted peak 
expiratory flow rate and forced expiratory flow (FEF 
25-75%) in children receiving a combination of 
salbutamol and ipratropium bromide than salbutamol 
alone.30  
Sharma and Madaan conducted a similar study in 
India on 50 children from 6 to 14 years of age suffering 
from mild to moderate exacerbation of acute asthma. 
After 60 minutes they found a significant increase in 
PEFR change (P<0.001) and a significant decrease in 
dyspnea score (P<0.05) and accessory muscle score (P< 
0.01) in group 2 (salbutamol-ipratropium bromide 
nebulization) as compared to group 1(salbutamol 
nebulization alone).16 
A Cochrane review of twenty trials by Griffith 
suggests that the number of hospital admissions 
decreases by the addition of ipratropium bromide to 
salbutamol even in those with moderate exacerbation 




Our study shows that there is no additional benefit of 
adding ipratropium bromide with salbutamol 
compared to salbutamol alone for the management of 
children with mild to moderate asthma attacks. This is 
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